ArticleCurrent medical imaging2026
CT Radiomics for the Early Identification of Fungal Co-infection in Immunocompromised Patients with Viral Pneumonia
Article in Current medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to establish and validate CT-based radiomics models combined with clinical data to identify Fungal Co-Infections (FCI) in immunocompromised patients with Viral Pneumonia (VP). MATERIALS AND
methodsA total of 406 patients (VP: 283; FCI: 123) from two hospitals were retrospectively enrolled and divided into training (n = 218), testing (n = 96), and external validation (n = 92) cohorts. Radiomics features were extracted from chest CT images. Feature selection was performed using the Least Absolute Shrinkage And Selection Operator (LASSO), and logistic regression models were built with clinical, radiomics, and combined inputs. Model performance was assessed using the Area Under the Receiver Operating Characteristic Curve (AUC), calibration, and Decision Curve Analysis (DCA).
resultsThe combined model achieved AUCs of 0.981 (95% CI: 0.959 - 0.992), 0.845 (95% CI: 0.762 - 0.950), and 0.835 (95% CI: 0.715 - 0.937) in the training, testing, and external validation cohorts, respectively, and consistently outperformed clinical-only and radiomics-only models. DISCUSSION: The model identified characteristic clinical and imaging differences between VP and FCI, including higher neutrophil counts, lower lymphocyte counts, and imaging markers such as reversed halo sign and solid nodules in FCI. These findings support the potential of radiomics as a noninvasive tool for early detection and risk stratification.
conclusionCT-based radiomics provides an effective approach for differentiating VP and FCI in immunocompromised patients, with potential to improve diagnosis and clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.